Trial reportBMC medicine2026
Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT).
Trial report in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05176002 (The Safety and Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma.), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Squamous Cell Carcinoma.
Who cites it
1 citing paper in PubMed.
- Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis.Clinical and translational radiation oncology · 2027Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCamrelizumab combined with radiotherapy may offer an effective neoadjuvant option for locally advanced esophageal squamous cell carcinoma while reducing chemotherapy-related toxicity. We assessed the efficacy and safety of this chemotherapy-sparing regimen.
methodsIn this single-arm phase II trial, adults with resectable thoracic esophageal squamous cell carcinoma received camrelizumab 200 mg intravenously every 3 weeks for two cycles, concurrently with radiotherapy to 41.4 Gy in 23 fractions, followed by esophagectomy 4-8 weeks later. The primary endpoint was major pathologic response (≤ 10% residual viable tumor) among patients undergoing resection. Secondary endpoints were R0 resection rate, pathologic complete response, treatment-related adverse events, postoperative complications, and survival outcomes.
trial registrationClinicalTrials.gov NCT05176002.
resultsTwenty-five patients were enrolled; three did not undergo surgery (one radiographic complete response with refusal of surgery, one disease progression, and one withdrawal). Twenty-two patients (88%) had esophagectomy, all with R0 resection. Major pathologic response occurred in 12 of 22 patients (54.5%), including pathologic complete response in 8 (36.4%). No grade 3 or higher treatment-related adverse events were observed; the most frequent toxicities were low-grade radiation esophagitis, leukopenia, dermatitis, and hypothyroidism. Postoperative complications were low grade. At a median follow-up of 36 months, five recurrences were recorded, with survival comparable to historical standard neoadjuvant cohorts.
conclusionsNeoadjuvant camrelizumab plus radiotherapy showed low toxicity, pathologic tumor regression, and favorable postoperative outcomes in resectable esophageal squamous cell carcinoma. This chemotherapy-sparing approach may be an alternative for patients who are unsuitable for or intolerant of standard chemotherapy-based neoadjuvant regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.